|
IFN-g |
Plasmodium falciparum |
CSF |
|
|
|
|
= |
|
|
|
|
84 |
CM patients: CSF < Serum |
John et al., 2008, Am J Trop Med Hyg |
Link |
|
IFN-g |
Plasmodium falciparum |
CSF (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
n.s. |
|
> |
|
466 |
+ correlation with IL-1a and TNF-a |
Kwiatkowski et al., 1990, Lancet |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
< |
|
|
|
106 |
Association between ↓ risk of CM and the IFNg-183T allele and the IFNg-183G/T genotype |
Cabantous et al., 2005, J Infect Dis |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
n.s. |
|
> |
200 |
N.I. |
Luty et al., 2000, Infect Immun |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
|
29 |
N.I. |
Perkmann et al., 2005, Cytokine |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
n.s. |
|
|
n.s. |
n.s. |
|
|
123 |
CM > HC |
Guiyedi et al., 2007, PLoS One |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
= |
135 |
CM, AM > HC; CM < AM; NCSM = HC |
Duarte et al., 2007, Malar J |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
48 |
Malaria (NCSM + UM) > HC (patients in the convalescent phase of malaria) |
Awandare et al., 2006, Clin Immunol |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
> |
129 |
NCSM > HC |
Perkins et al., 2001, J Infect Dis |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
= |
= |
|
> |
98 |
CM, NCSM, UM > endemic HC; + correlation with plasma total IgE |
Duarte et al., 2007, Malar J |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
= |
|
= |
|
|
|
|
|
|
48 |
N.I. |
Deloron et al., 1994, Clin Infect Dis |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
< |
|
|
< |
= |
|
> |
97 |
SM > HC; endemic HC = non-endemic HC |
Prakash et al., 2006, J Infect Dis |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
111 |
SM < HC |
Hermsen et al., 2003, Clin Exp Immunol |
Link |
|
IFN-g |
Plasmodium falciparum |
Plasma |
|
= |
< |
|
|
|
|
|
|
287 |
cerebral symptoms < cerebral symptoms + coma + MOD; + correlation with parasite count and hematocrit; high levels were associated with hyperparasitemia, jaundice and hemodynamic shock |
Day et al., 1999, J Infect Dis |
Link |
|
IFN-g |
Plasmodium falciparum |
Serum |
|
|
|
|
|
> |
|
|
|
177 |
CM > AM; UM > AM |
Al-Yaman et al., 1998, Trans R Soc Trop Med Hyg |
Link |
|
IFN-g |
Plasmodium falciparum |
Serum |
> |
|
|
|
|
> |
|
|
> |
217 |
N.I. |
John et al., 2006, J Infect Dis |
Link |
|
IFN-g |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
> |
54 |
+ correlation with IL-10 |
Wenisch et al., 1995, Clin Immunol Immunopathol |
Link |
|
IFN-g |
Plasmodium falciparum |
Serum (PM) |
|
|
= |
|
= |
|
|
|
|
19 |
N.I. |
Armah et al., 2007, Malar J |
Link |
|
IFN-g |
Plasmodium falciparum (1 Plasmodium vivax) |
Brain (PM)-IHC |
|
|
> |
|
> |
|
|
|
|
7 |
CM(falciparum) > SM(vivax) |
Maneerat et al., 1999, Southeast Asian J Trop Med Public Health |
Link |
|
IFN-g |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
> |
255 |
UM vivax = UM falciparum > HC; P. vivax: anemic patients = non-anemic patients; patients without parasite-specific IgM > patients with parasite-specific IgM; patients without parasite-specific IgG < patients with parasite-specific IgG; P. falciparum: anemic patients = non-anemic patients; patients without parasite-specific IgM, IgG = patients with parasite-specific IgM, IgG |
Fernandes et al., 2006, Clin Vaccine Immunol |
Link |
|
IFN-g |
Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
> |
99 |
HC were the same patients 3 weeks after treatment; nontransmitters = transmitters |
Abeles et al., 2013, Am J Trop Med Hyg |
Link |
|
IFN-g |
Plasmodium vivax |
Serum |
|
|
|
|
|
|
|
|
> |
41 |
Thrombocytopenic patients = non-thrombocytopenic patients |
Coelho et al., 2013, PLoS One |
Link |
|
IFN-g mRNA |
Plasmodium falciparum |
Blood |
|
|
|
|
|
|
> |
n.s. |
= |
88 |
SM = HC |
Lourembam et al., 2013, Cytokine |
Link |
|
IgA-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
= |
<* |
|
|
233 |
Follow up: CM > SMA and UM = CM, SMA; in patients with SMA or CM: levels at admission = follow up; protective against CM |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgE against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
n.s. |
|
> |
256 |
↑ levels were associated with ↑ risk of SM |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgE-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
= |
|
|
233 |
Follow up: CM = SMA = UM; in patients with SMA: levels at admission = follow up; in patients with CM: levels at admission >* follow up; independent predictor of CM |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgG against a-galactosyl |
Plasmodium falciparum |
CSF |
|
|
|
|
|
|
|
|
|
65 |
CM > NM |
Ravindran et al., 1992, Trans R Soc Trop Med Hyg |
Link |
|
IgG against b-tubulin 3 (TBB3) (brain) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
98 |
CM > HC |
Bansal et al., 2009, PLoS One |
Link |
|
IgG against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
> |
256 |
Malaria: predominantly IgG1, IgG2 or IgG3 (↓ IgG4) |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgG against C2 fragment of RAP1 |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
|
|
|
269 |
Levels were ↓ at follow up (after 1 month) in CM and SMA patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against cardiolipin (CL) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
99 |
Incidence: malaria (CM + UM) > HC |
Soni et al., 1993, S Afr Med J |
Link |
|
IgG against cardiolipin (CL) |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
|
255 |
Number of UM patients > number of HC; number of P. vivax patients = number of P. falciparum patients |
Fernandes et al., 2006, Clin Vaccine Immunol |
Link |
|
IgG against conserved C-terminal ATS domain of PfEMP-1 |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
= |
|
= |
89 |
Semi-immune adults (IA) > HC; T cell response to rATSPfEMP1: IA > SM = UM > HC; T cell IFN-g and IL-4 response to rATSPfEMP1: IA = SM = UM > HC |
Das et al., 2007, Parasitol Int |
Link |
|
IgG against conserved C-terminal region of MSP119 |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
> |
= |
|
|
269 |
Prevalence rate of anti-MSP-1: CM > SMA, UM; levels were ↓ at follow up (after 1 month) in CM and SMA patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against conserved C-terminal region of MSP119 |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
|
= |
|
|
340 |
SM > HC; prevalence of anti-MSP119-IgG: SM < UM independent of age, malaria (SM + UM) > HC; no IgG detected in < 1 year patients; no ↓ in prevalence of IgG 28 days after infection |
A-Elgadir et al., 2008, Parasitol Res |
Link |
|
IgG against conserved C-terminal region of MSP119 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
52 |
Anti-MSP119-IgG > anti-MSP1block2-IgG |
Cavanagh et al., 1998, J Immunol |
Link |
|
IgG against conserved C-terminal region of MSP119 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
149 |
+ correlation with number of recognized MSP Ags (MSP119 - MSP2A - MSP2B) and random blood glucose; - correlation with number of clinical malaria attacks in past 2 years and fever duration (after exclusion of 2 outliers); |
Giha et al., 2009, Eur J Clin Microbiol Infect Dis |
Link |
|
IgG against conserved C-terminal region of MSP142 |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
> |
|
|
|
269 |
Prevalence rate of anti-MSP1: CM > SMA, UM; levels were ↓ at follow up (after 1 month) in CM and SMA patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against conserved C-terminal region of MSP2 (K1 17/14) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
> |
< |
|
|
269 |
SMA patients: undetectable levels against C-terminal region of anti-MSP2 (K1 17/14); prevalence rate of anti-MSP2 (K1 17/14): CM > SMA; levels were ↓ at follow up (after 1 month) in CM patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against conserved N-terminal block 1 region of MSP1 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
52 |
Rarely detected |
Cavanagh et al., 1998, J Immunol |
Link |
|
IgG against dimorphic type of MSP2 (FC27-type protein T9/105 12/6) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
> |
< |
|
|
269 |
Prevalence rate of anti-MSP2 (T9/105 12/6): CM > SMA, UM; levels were ↓ at follow up (after 1 month) in CM patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against dimorphic type of MSP2 (FC27-type protein T9/105 12/6) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
545 |
IgG3 > IgG1 > IgG2, IgG4; IgG FC27 > IgG 3D7; < 5 years old: IgG1, IgG3: UM > SM = HC; - correlation between anti-MSP2FC27-IgG1 and risk of SM; > 5 years old: IgG1, IgG3: UM > SM > HC |
Iriemenam et al., 2009, Vaccine |
Link |
|
IgG against dimorphic type of MSP2A (IC1/3D7-type protein T9/96 13/14) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
= |
= |
|
|
269 |
Prevalence rate of anti-MSP2 (IC1/3D7 T9/96 13/14): CM > SMA; levels were ↓ at follow up (after 1 month) in CM patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against dimorphic type of MSP2A (IC1/3D7-type protein T9/96 13/14) |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
|
< |
|
> |
340 |
SM > HC; prevalence of anti-MSP2A-IgG: SM < UM, malaria (SM + UM) > HC; no ↓ in prevalence of IgG 28 days after infection |
A-Elgadir et al., 2008, Parasitol Res |
Link |
|
IgG against dimorphic type of MSP2A (IC1/3D7-type protein T9/96 13/14) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
545 |
IgG3, IgG1 > IgG2, IgG4; IgG FC27 > IgG 3D7; + correlation between anti-MSP2-IgG3 and protection from SM; HC: IgG3 < IgG1; malaria: IgG3 > IgG1; > 5 years old: IgG1UM > IgG1SM |
Iriemenam et al., 2009, Vaccine |
Link |
|
IgG against dimorphic type of MSP2B (GF/88) |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
|
= |
|
= |
340 |
SM = HC; prevalence of anti-MSP2B-IgG: SM < UM, malaria (SM + UM) > HC; no ↓ in prevalence of IgG 28 days after infection |
A-Elgadir et al., 2008, Parasitol Res |
Link |
|
IgG against full-length FC27-type protein or against polymorphic regions of MSP2 |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
= |
= |
|
|
269 |
N.I. |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against g-aminobutyric acid synthesizing enzyme (GAD) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
= |
|
|
= |
199 |
HC = AM = NM-CNS |
Lang et al., 2004, J Infect Dis |
Link |
|
IgG against highly conserved N-terminal DBL-1a domains of PfEMP-1 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
|
122 |
+ correlation with anti-rifin-IgG in acute phase samples; both anti-rifin-IgG and anti-DBL-1a-IgG contribute to the overall antibody response to VSA |
Abdel-Latif et al., 2004, Am J Trop Med Hyg |
Link |
|
IgG against MSP3 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
545 |
IgG3, IgG1 > IgG2, IgG4; malaria: IgG3 > IgG1; HC: IgG3 < IgG1; for IgG3 in > 5 years old: SM < UM > HC |
Iriemenam et al., 2009, Vaccine |
Link |
|
IgG against MSPall (MSP119+ MSP2A + MSP2B) |
Plasmodium falciparum |
Plasma |
= |
|
|
|
|
|
|
|
|
340 |
Prevalence of anti-MSPall-IgG: SM < UM, malaria (SM + UM) > HC; proportion of patients that recognized all 3 Ags: SM < UM; anti-MSP119-IgG > anti-MSP2B-IgG; + correlation between prevalence of anti-MSP1all-IgG and age; prevalence rate against at least 1 of the 3 Ags: malaria patients with hypotension (HTN) = CM, HTN > SMA, HTN and CM > convulsion-associated malaria; no ↓ in prevalence of IgG 28 days after infection |
A-Elgadir et al., 2008, Parasitol Res |
Link |
|
IgG against muscle nicotinic acetylcholine receptors (nAChR) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
199 |
Undetectable |
Lang et al., 2004, J Infect Dis |
Link |
|
IgG against N-terminus of SERA5 (SE36) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
< |
|
|
205 |
Prevalence of anti-SE36-IgG: SM < UM (6-24 months age group), SM = UM (children between 25-59 months age group); SM: 25-59 months age group > 6-12 months age group; + correlation with packed cell volume and Hb; - correlation with parasite density and % of pigmented WBC; UM: temperature: ↑ IgG < ↓ IgG |
Okech et al., 2006, Am J Trop Med Hyg |
Link |
|
IgG against non-erythroid spectrin (a and b) (brain) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
> |
|
|
= |
123 |
Intensity of the reactivity to band-0 (spectrin): CM > NCSM, UM, + correlation with TNF-a |
Guiyedi et al., 2007, PLoS One |
Link |
|
IgG against non-infected RBC protein extract |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
= |
= |
|
|
98 |
Malaria (CM + SM + UM) > HC |
Bansal et al., 2009, PLoS One |
Link |
|
IgG against non-infected RBC protein extract |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
|
|
|
|
255 |
Number of UM patients > number of HC; number of P. vivax patients > number of P. falciparum patients; P. vivax: + correlation with MIF; P. falciparum: + correlation with IL-12 |
Fernandes et al., 2006, Clin Vaccine Immunol |
Link |
|
IgG against P-/Q- and N-type voltage-gated calcium channels (VGCC) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
> |
|
|
> |
299 |
HC = AM = NM-CNS = undetectable; no positive antibody titers in 6 CM†; + correlation with parasitemia; + correlation between P-/Q- type and N-type VGCC antibody titers |
Lang et al., 2004, J Infect Dis |
Link |
|
IgG against PfEMP-13D7 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
60 |
HC with a history of malaria: no difference in IgG directed against a particular group (A, B/A, B, C, B/C) or domain type (a, b, g, d, e, x), acquisition of IgG in a fixed sequence, transmission-independent and age- dependent; rate of IgG acquisition is dependent on the intensity of transmission |
Joergensen et al., 2007, J Immunol |
Link |
|
IgG against phosphatidylcholine (PC) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
= |
131 |
N.I. |
Jakobsen et al., 1993, Immunology |
Link |
|
IgG against phosphatidylcholine (PC) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
> |
|
|
> |
49 |
CM† = UM; IgG4 N.D.; IgG3 > IgG2 > IgG1; IgG1: CM > CM†, CM = UM; IgG2 + IgG3: CM† = CM = UM; - correlation between IgG1 and TNF-a |
Das et al., 1996, Clin Exp Immunol |
Link |
|
IgG against phosphatidylinositol (PI) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
= |
131 |
N.I. |
Jakobsen et al., 1993, Immunology |
Link |
|
IgG against phosphatidylinositol (PI) |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
= |
|
|
|
82 |
N.I. |
Facer et al., 1994, Clin Exp Immunol |
Link |
|
IgG against Plasmodial GPI |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
135/204/341 |
Pediatric patients < adult patients; + association with age; AM >* UM; AM and patients with fever and low par: anti-GPI-IgGMay = anti-GPI-IgGOctober; UM: anti-GPI-IgGMay < anti-GPI-IgGOctober; < 2 years old: ↓ prevalence of anti-GPI-IgG; anti-GPI-IgG prevalence: CM = SMA = UM > NM |
De Souza et al., 2002, Infect Immun |
Link |
|
IgG against Plasmodial GPI |
Plasmodium falciparum |
Serum |
|
|
|
|
|
= |
= |
|
> |
606 |
Proportion of patients with anti-GPI-IgG: SM = UM, SM† > HC, SM > HC, CM > HC, SMA + hyperparasitemia = UM = HC,; + correlation with age and absolute parasitemia; children enrolled early = end < middle of the transmission season; levels ↓ in the dry season |
Cissoko et al., 2006, Am J Trop Med Hyg |
Link |
|
IgG against Plasmodial GPI |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
> |
350/198 |
< 2 years old: no anti-GPI-IgG in ~50% of the children, ~40% had short-lived Ab responses and ~10% had long-lived Ab-responses; ~75% of 7-8 years old and all adults had long-lived Ab responses; + association with age, Hb and temperature |
Naik et al., 2000, J Exp Med |
Link |
|
IgG against rifin (rif-29) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
116 |
SM > HC/NM; IgG1, IgG3 > IgG2, IgG4 |
Schreiber et al., 2006, Microbes Infect |
Link |
|
IgG against rifin (rif-29, -40, -44, -50) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
102 |
SM < AM; - correlation with time to parasite clearance; anti-rifin-IgG peaked 1 month after admission and remained ↑ until end of measurement (after 24 months) during which period none of the children became sick of malaria |
Abdel-Latif et al., 2003, Infect Immun |
Link |
|
IgG against rifin (rif-29, -40, -44, -50) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
122 |
+ correlation with anti-DBL-1a-IgG in acute phase samples; - correlation with anti-VSA-IgG in UM convalescent phase samples; both anti-rifin-IgG and anti-DBL-1a-IgG contribute to the overall antibody response to VSA |
Abdel-Latif et al., 2004, Am J Trop Med Hyg |
Link |
|
IgG against the ectodomein of AMA1 |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
|
|
|
|
269 |
Prevalence rate of anti-AMA1: CM > SMA*; levels were ↓ at follow up (after 1 month) in CM patients |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG against the ectodomein of AMA1 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
< |
|
|
545 |
IgG1 > IgG3 > IgG2, IgG4; + correlation with protection from SM; < 5 years old: UM = HC[>]p=0.051; > 5 years old: UM > HC |
Iriemenam et al., 2009, Vaccine |
Link |
|
IgG against total brain protein extract |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
123 |
Median number of cerebral antigens recognized by plasma IgG: CM = NCSM = UM > HC; Proportion of individuals with a ↑ number of bands (> 12): CM = NCSM > UM, HC; reactivity to brain antigens (factor 1 score): CM >* NCSM = UM = HC > European HC; factor 1 score was particularly ↑ in CM patients with ↑ plasma TNF-a |
Guiyedi et al., 2007, PLoS One |
Link |
|
IgG against total brain protein extract |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
98 |
Malaria (CM + SM + UM) > HC; median number of cerebral antigens recognized by plasma IgG: malaria (CM + SM + UM) > HC; reactivity to brain antigens (factor 1 score): CM > SM = UM > HC; similar profile reactivity to brain antigens for Gabonese children (67) and Indian patients, but with different predominant activity (Gabonese predominantly recognize spectrin, Indians beta tubulin 3); + correlation with TNF-a, TGF-b, IL-10 and IL-1b |
Bansal et al., 2009, PLoS One |
Link |
|
IgG against voltage-gated potassium channels (VGKC) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
= |
|
|
= |
199 |
HC = AM = NM-CNS |
Lang et al., 2004, J Infect Dis |
Link |
|
IgG against VSA |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
< |
|
|
200 |
Anti-VSA-IgG levels/person: ↑ from the acute to the healthy phase; + correlation with delay to first reinfection; + correlation between healthy phase anti-VSA-IgG and protection from malaria (UM); - correlation with malaria attack rate; - correlation with age (convalescent phase); - correlation between malaria attack rates and recognition of heterologous isolates |
Tebo et al., 2002, Am J Trop Med Hyg |
Link |
|
IgG against ↑ polymorphic N-terminal block 2 region of MSP1 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
|
|
|
52 |
Anti-MSP119-IgG > anti-MSP1block2-IgG |
Cavanagh et al., 1998, J Immunol |
Link |
|
IgG against ↑ polymorphic N-terminal block 2 region of MSP1 (RO33 type) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
> |
= |
|
|
269 |
Prevalence rate of anti-MSP1: CM > UM; Levels were ↓ at follow up (after 1 month) in CM patients; + correlation with full recovery of CM |
Dobaño et al., 2008, J Infect Dis |
Link |
|
IgG anti-IgE |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
22 |
Malaria > HC |
Perlmann et al., 1997, Infect Immun |
Link |
|
IgG-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
>* |
= |
|
|
233 |
Follow up: CM > SMA = UM; in patients with SMA: levels at admission = follow up; in patients with CM: levels at admission > follow up; independent predictor of CM |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgG-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
> |
> |
|
|
259 |
CM, SMA > AM; levels ↓ following treatment; + correlation with parasite density (SMA); - correlation with Hb levels (AM) |
Mibei et al., 2005, Am J Trop Med Hyg |
Link |
|
IgG1 against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
< |
|
> |
256 |
SM > HC; + correlation with protection from SM |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgG1 against rifin (rif-29) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
116 |
CM = HC/NM; NCSM = HC/NM; prevalence of anti-rif29-IgG1: CM = NCSM = HC/NM |
Schreiber et al., 2006, Microbes Infect |
Link |
|
IgG1,IgG3 against GLURP (R0 and R2) |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
< |
|
|
545 |
> 5 years: IgG3 > IgG1 > IgG2, IgG4; < 5 years: IgG1 > IgG3 > IgG2, IgG4, IgG4; + correlation between anti-GLURPR0-IgG1 and protection from SM; > 5 years old: SM,UM > HC |
Iriemenam et al., 2009, Vaccine |
Link |
|
IgG1-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
= |
= |
|
|
233 |
Follow up: CM > SMA = UM; in patients with SMA: levels at admission = follow up; in patients with CM: levels at admission > follow up |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgG2 against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
n.s. |
|
> |
256 |
SM > HC; + correlation* with protection from SM in patients with FcgRIIa-H131 |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgG2 against rifin (rif-29) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
116 |
CM > HC/NM; NCSM = HC/NM; prevalence of anti-rif29-IgG2: CM > NCSM = HC/NM |
Schreiber et al., 2006, Microbes Infect |
Link |
|
IgG2-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
n.s. |
= |
|
|
233 |
Follow up: CM = SMA = UM; in patients with SMA: levels at admission = follow up; in patients with CM: levels at admission > follow up |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgG3 against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
n.s. |
|
> |
256 |
SM > HC |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgG3 against rifin (rif-29) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
116 |
CM > HC/NM; NCSM > HC/NM; prevalence of anti-rif29-IgG3: CM = NCSM > HC/NM |
Schreiber et al., 2006, Microbes Infect |
Link |
|
IgG3-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
= |
|
|
= |
= |
|
|
233 |
Follow up: CM = SMA = UM; in patients with SMA: levels at admission = follow up; in patients with CM: levels at admission > follow up |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgG4 against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
= |
256 |
+ correlation* with risk of SM |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgG4 against rifin (rif-29) |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
|
|
|
116 |
CM > HC/NM; NCSM = HC/NM; prevalence of anti-rif29-IgG4: CM > HC/NM, NCSM = HC/NM; CM = NCSM |
Schreiber et al., 2006, Microbes Infect |
Link |
|
IgG4-immune complexes (IC) |
Plasmodium falciparum |
Plasma |
|
|
> |
|
|
>* |
= |
|
|
233 |
Follow up: CM > SMA and UM = CM, SMA; in patients with SMA or CM: levels at admission >* follow up; independent predictor of SMA |
Mibei et al., 2008, Parasite Immunol |
Link |
|
IgG:IgE |
Plasmodium falciparum |
Serum |
|
|
|
|
|
|
< |
|
|
70 |
N.I. |
Perlmann et al., 2000, Am J Trop Med Hyg |
Link |
|
IgM against C-terminus of Pf332-C231 |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
= |
|
|
256 |
N.I. |
Nasr et al., 2007, Scand J Immunol |
Link |
|
IgM against PC |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
= |
131 |
N.I. |
Jakobsen et al., 1993, Immunology |
Link |
|
IgM against PC |
Plasmodium falciparum |
Serum |
= |
|
|
|
|
|
|
|
> |
49 |
N.I. |
Das et al., 1996, Clin Exp Immunol |
Link |
|
IgM against PI |
Plasmodium falciparum |
Plasma |
|
|
|
|
|
|
> |
|
= |
131 |
N.I. |
Jakobsen et al., 1993, Immunology |
Link |
|
IgM against PI |
Plasmodium falciparum, Plasmodium vivax |
Plasma |
|
|
|
|
|
< |
|
|
|
82 |
N.I. |
Facer et al., 1994, Clin Exp Immunol |
Link |
|
IgM against Plasmodial GPI |
Plasmodium falciparum |
Serum |
|
|
|
|
|
> |
= |
|
> |
606 |
Proportion of patients with anti-GPI-IgM: SM = UM > HC, CM > HC, SM† > HC, SMA + hyperparasitemia = UM, HC; IgM in HC: children enrolled early > middle = end of the transmission season; IgM in malaria: children enrolled early = middle = end of the transmission season |
Cissoko et al., 2006, Am J Trop Med Hyg |
Link |